Items where authors include "Kipps, TJ"

Article

Solman, IG, Blum, LK, Hoh, HY et al. (11 more authors) (2020) Ibrutinib Restores Immune Cell Numbers and Function in First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia. Leukemia Research. 106432. p. 106432. ISSN 0145-2126

Munir, T, Brown, JR, O'Brien, S et al. (17 more authors) (2019) Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. American Journal of Hematology, 94 (12). pp. 1353-1363. ISSN 0361-8609

O'Brien, SM, Byrd, JC, Hillmen, P orcid.org/0000-0001-5617-4403 et al. (15 more authors) (2019) Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. American Journal of Hematology, 94 (5). pp. 554-562. ISSN 0361-8609

Barrientos, JC, Burger, JA, Byrd, JC et al. (5 more authors) (2019) Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. Leukemia & Lymphoma, 60 (4). pp. 1000-1005. ISSN 1042-8194

Kater, AP, Seymour, JF, Hillmen, P orcid.org/0000-0001-5617-4403 et al. (12 more authors) (2019) Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. Journal of Clinical Oncology, 34 (4). pp. 269-277. ISSN 0732-183X

Robak, T, Burger, JA, Tedeschi, A et al. (23 more authors) (2018) Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies. American Journal of Hematology, 93 (11). pp. 1402-1410. ISSN 0361-8609

Seymour, JF, Kipps, TJ, Eichhorst, B et al. (17 more authors) (2018) Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. New England Journal of Medicine, 378 (12). pp. 1107-1120. ISSN 0028-4793

Brown, JR, Hillmen, P orcid.org/0000-0001-5617-4403, O'Brien, S et al. (27 more authors) (2018) Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE(TM) study in patients with previously treated CLL/SLL. Leukemia, 32. pp. 83-91. ISSN 0887-6924

Brown, JR, Moslehi, J, O' Brien, S et al. (24 more authors) (2017) Characterization Of Atrial Fibrillation Adverse Events Reported In Ibrutinib Randomized Controlled Registration Trials. Haematologica, 102 (10). pp. 1796-1805. ISSN 0390-6078

Buehler, A, Wendtner, C-M, Kipps, TJ et al. (17 more authors) (2016) Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer Journal, 6. ARTN e404. ISSN 2044-5385

Burger, JA, Tedeschi, A, Barr, PM et al. (31 more authors) (2015) Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. New England Journal of Medicine, 373 (25). pp. 2425-2437. ISSN 0028-4793

Proceedings Paper

Burger, J, Tedeschi, A, Barr, PM et al. (32 more authors) (2016) International, randomized phase 3 study results: Ibrutinib versus Chlorambucil in patients 65 years and older with treatment-naive CLL (RESONATE-2 (TM)). In: Oncology Research and Treatment. Annual conference of the German, Austrian and Swiss Societies for Haematology and Medical Oncology, 14-18 Oct 2016, Leipzig, Germany. Karger Publishers , p. 6.